Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B 1 and B 2 receptors

British Journal of Pharmacology

Volumn 150, Issue 3, 2007, Pages 369-379

  Morissette, G ^a   Houle, S ^a,c   Gera, L ^b   Stewart, J M ^b   Marceau, F ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

B 9870 (CU201); B 1 receptor; B 2 receptor; Biased agonist; Bradykinin; MDA MB 231 cells; Pharmacological antagonism

Indexed keywords

ANATIBANT; ARACHIDONIC ACID; B 9870; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR; CALCIUM ION; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PARTIAL AGONIST; UNCLASSIFIED DRUG;

AORTA CONSTRICTION; APOPTOSIS; ARTICLE; ASSAY; CELL GROWTH; CELL LINE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOCYTOSIS; FLUORESCENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; JUGULAR VEIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RABBIT; VENOCONSTRICTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; OLIGOPEPTIDES; RABBITS; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2;

EID: 33846874106     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706982     Document Type: Article

References (36)

1. 2 receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. J Pharmacol Exp Ther 297: 19-26.
2. 2 receptor. J Pharmacol Exp Ther 275: 1623-1630.
3. Blaukat A, Abd Alla S, Lohse MJ, Müller-Esterl W (1996). Ligand-induced phosphorylation/ dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J Biol Chem 271: 32366-32374.
4. 2 receptors and phosphatidylinositol 3-kinase γ. Mol Pharmacol 66: 293-301.
5. Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G et al. (2002a). Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a 'biased agonist' mechanism. Proc Natl Acad Sci USA 99: 4608-4613.
6. Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY et al. (2002b). Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res 8: 1280-1287.
7. 1 MF-2 smooth muscle cells. J Biol Chem 272: 17858-17866.
8. 2 receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist. Br J Pharmacol 131: 1553-1560.
9. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92: 7686-7689.
10. 2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists. J Biol Chem 274: 29603-29606.
11. 2 receptor antagonist, Hoe 140, in isolated blood vessels from different species. Br J Pharmacol 112: 683-689.
12. Gera L, Stewart JM, Whalley E, Burkard M, Zuzack JS (1996). A new class of potent bradykinin antagonist dimers. Immunopharmacology 33: 178-182.
13. 2 receptor in caveolae. J Cell Sci 111: 917-928.
14. 2 receptor. Hypertension 35: 1319-1325.
15. 2 receptors. Hypertension 41: 611-617.
16. Kenakin TP (1987). Agonist efficacy. In: Pharmacological Analysis of Drug-receptor Interaction. Raven Press: New York, pp. 183-203.
17. Leeb-Lundberg LMF, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL (2005). International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27-77.
18. Leslie FM (1987). Methods used for the study of opioid receptors. Pharmacol Rev 39: 197-249.
19. MacKinnon AC, Waters C, Jodrell D, Haslett C, Sethi T (2001). Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem 276: 28083-28091.
20. Marceau F, Sabourin T, Houle S, Fortin JP, Petitclerc E, Molinaro G et al. (2002). Kinin receptors: functional aspects. Int Immunopharmacol 2: 1729-1739.
21. Mathieu MC, Sawyer N, Greig GM, Hamel M, Kargman S, Ducharme Y et al. (2005). The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett 100: 139-145.
22. Melikov K, Chernomordik LV (2005). Arginine-rich cell penetrating peptides: from endosomal uptake to nuclear delivery. Cell Mol Life Sci 62: 2739-2749.
23. 1 receptor: effects at the rabbit receptor. J Pharmacol Exp Ther 311: 1121-1130.
24. Morissette G, Petitclerc E, Marceau F (2004b). Loss of function of vascular smooth muscle cells by nitric oxide-dependent and - independent interactions with tumorigenic cells. Int J Cancer 112: 830-839.
25. Munoz CM, Leeb-Lundberg FLM (1992). Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradative pathways. J Biol Chem 267: 303-309.
26. 2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. J Biol Chem 274: 12738-12747.
27. 2 receptor antagonist. Immunopharmacology 43: 187-194.
28. 1 receptor to caveolae-related rafts. Mol Pharmacol 61: 546-553.
29. Schroeder C, Beug H, Müller-Esterl W(1997). Cloning and functional characterization of the ornithokinin receptor. Recognition of the major kinin receptor antagonist, HOE140, as a full agonist. J Biol Chem 272: 12475-12481.
30. Stewart JM, Gera L, Chan DC, Bunn PA, York EJ, Simkeviciene V et al. (2002). Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol 80: 275-280.
31. Stewart JM, Gera L, Chan DC, Whalley ET, Hanson WL, Zuzack JS (1997). Potent, long-acting bradykinin antagonists for a wide range of applications. Can J Physiol Pharmacol 75: 719-724.
32. Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA et al. (2005). Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides 26: 1288-1291.
33. Stewart JM, Gera L, Hanson W, Zuzak JS, Burkard M, McCullough R et al. (1996). A new generation of bradykinin antagonists. Immunopharmacology 31: 51-60.
34. 1 receptor antagonist. J Am Chem Soc 125: 7516-7517.
35. Taub JS, Guo R, Leeb-Lundberg LMF, Madden JF, Daaka Y (2003). Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 63: 2037-2041.
36. Tung CH, Weissleder R (2003). Arginine containing peptides as delivery vectors. Adv Drug Deliv Rev 55: 281-294.